Summary by Futu AI
Recursion Pharmaceuticals, Inc. (RXRX) reported that Dar Zavain, a person associated with the company, was granted 13,097 shares of Class A Common Stock on June 3, 2024. The transaction was completed at no cost to the recipient, indicating that the shares were likely awarded as part of a compensation package or incentive plan. Following this transaction, Zavain's direct holdings in the company increased to a total of 102,153 shares. The grant is part of the company's ongoing efforts to align the interests of its key personnel with those of its shareholders.